FDA Approves MyChoice CDx as Companion Diagnostic for Zejula in Ovarian Cancer
The approval makes MyChoice CDx the sole FDA-approved test in the US to identify HRD-positive patients eligible for niraparib maintenance therapy.
Latest Articles
Editor's Top Picks
Diabetes Testing Moves Earlier—and Gets More Complex
As the 2026 ADA Standards of Care emphasize earlier identification and more precise classification of diabetes, clinical laboratories are rethinking workflows, assay menus, and their role in detection.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
Siemens Healthineers Expands Brain Health Research Portfolio with New Blood-Based Tau Assays
Siemens Healthineers has introduced two new blood-based tau assays for research use on the Atellica platform, expanding its brain health portfolio with tests aimed at advancing neurodegenerative disease research.
Equipment & Supply Spotlight
Quest Diagnostics Launches AI Tool to Help Patients Interpret Lab Results
The AI companion analyzes up to five years of personal lab data within the company's patient portal to explain test results and identify health trends.
News, Know-How & Standards
Disease Detection & Understanding
ADDF Launches Third Phase of Diagnostics Accelerator with $50 Million to Advance Alzheimer’s Blood Tests and AI Biomarkers
The new funding brings the initiative's total to $150 million and will focus on tau pathology, multi-marker panels, and AI-driven diagnostics.
